Help with Spinal Muscular Atrophy Drug Formulation
10 May 2017
Bionest Partners (a strategy consultancy specialized in healthcare industry) is currently working with a pharmaceutical company to assess a new potential oral drug for individuals with spinal muscular atrophy (SMA). The organisation is conducting a people-oriented study to better understand the needs and the daily life of individuals with SMA. The aim for the pharmaceutical company is to improve the formulation of this new product and ensure that this drug will be as adapted as possible to those with SMA.
To complete this study, Bionest Partners wishes to conduct 60-minute phone interviews with individuals who have SMA and/or caregivers.
Bionest Partners would like to interview:
- Individuals with type 2, 3 or 4 SMA, aged 12+ (please note: young people under 18 will need parental / guardian permission to take part)
- Caregivers of individuals with type 2, 3 or 4 SMA.
These interviews will stay strictly confidential and any individual comment will remain anonymous.
Your involvement in this study is voluntary. You will be compensated for your time and will receive £100 upon completion of the interview if you are selected to take part.
If you are interested in taking part or if you want to have more information, please get in touch with Margaux Verdu by emailing email@example.com